Related Experiment Videos
The RET proto-oncogene in human cancers
1Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio, OH 43210, USA.
Oncogene
|December 15, 2000
Summary
The RET proto-oncogene drives cancer through gene rearrangements in thyroid cancer and mutations in inherited endocrine syndromes. Understanding RET activation pathways is key to developing new cancer treatments.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- The RET proto-oncogene plays a critical role in human cancer development.
- RET activation occurs via somatic rearrangements or germline mutations.
- These alterations lead to constitutive activation and drive tumorigenesis.
Purpose of the Study:
- To investigate the biological effects and signaling pathways of different RET activation forms.
- To explore the correlation between RET mutation types and cancer phenotypes.
- To identify novel therapeutic strategies for RET-driven cancers.
Main Methods:
- Analysis of RET rearrangements in papillary thyroid carcinomas.
- Identification of germline RET mutations in multiple endocrine neoplasia type 2 (MEN 2).
- In vitro studies using cultured cells and in vivo studies using genetically engineered animal models to examine RET signaling pathways.
Main Results:
- Somatic RET rearrangements are common in radiation-induced papillary thyroid carcinomas.
- Germline point mutations in RET cause constitutive tyrosine kinase activity, leading to MEN 2.
- Specific RET mutations correlate with distinct clinical cancer phenotypes.
- RET signaling pathways have been elucidated in various models.
Conclusions:
- RET activation is a significant driver in both sporadic and inherited cancers.
- Understanding RET mutation-specific pathways is crucial for targeted therapies.
- Further research into RET signaling may yield novel prevention and treatment strategies for thyroid cancer and MEN 2.